Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

“…Richter syndrome (RS) is the transformation of chronic lymphocytic leukaemia (CLL) into an aggressive lymphoma, most commonly diffuse large B cell lymphoma (DLBCL) (Visentin et al , , ; Mauro et al , ). Anthracycline‐ or platinum‐based regimes provide complete response (CR) rates of 20–30% in patients with a median survival of 8 months; there are currently no standard salvage approaches for RS (Vitale & Ferrajoli 2016: see Appendix S1).…”

Peripheral nervous system involvement in lymphomas

“…12,13 Biological features are associated with the different clinical expression of CLL/SLL: in the indolent cases, no genetic abnormalities in the tumor suppressor gene TP53 and no mutated immunoglobulin heavy-chain gene are usually found, whereas in the aggressive cases, TP53 gene abnormalities and/or complex karyotypes are typically detected. 12,14 Common etiologies of neuropathy in CLL are viral (varicella zoster virus, VZV; hepatitis C virus, HCV), iatrogenic (ibrutinib, lenalidomide), immune-mediated, idiopathic, rarely due to peripheral nerve invasion by leukemic cells 15,16 or light chain amyloidosis. 17 We have recently reported on a cohort of 816 CLL patients, 19 (2.2%) of whom had neuropathy.…”

Angiotensin receptor signaling in sickle cell anemia has a reno‐protective effect on urine concentrating ability but results in sickle glomerulopathy

“…BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome Richter syndrome (RS) is the transformation of chronic lymphocytic leukaemia (CLL) into an aggressive lymphoma, most commonly diffuse large B cell lymphoma (DLBCL) (Visentin et al, 2015(Visentin et al, , 2017Mauro et al, 2017). Anthracycline-or platinum-based regimes provide complete response (CR) rates of 20-30% in patients with a median survival of 8 months; there are currently no standard salvage approaches for RS (Vitale & Ferrajoli 2016: see Appendix S1).…”